

Supplemental Figure 1. Effect of $CRIP_{1a}$ over-expression on [³H]SR141716A saturation binding in CB₁-HEK cell membranes. Membranes from CB₁-HEK or CB₁-HEK-CRIP_{1a} cells with were incubated as described in Methods with varying concentrations of [³H]SR141716A. Data are mean % stimulation ± SEM (n = 8).



Supplemental Figure 2. Representative quantitative immunoblot of $CRIP_{1a}$ protein. Lane 1: molecular weight marker. Lanes 2 - 6: purified $CRIP_{1a}$. Lanes 7 and 8: membranes from CB_1 -HEK cells without transfected $CRIP_{1a}$ (- Cr). Lanes 8 and 10: membranes from CB_1 -HEK cells with stably transfected $CRIP_{1a}$ (+ Cr).



Supplemental Figure 3. $CRIP_{1a}$ -immunoreactivity in the rat cerebellar cortex is abolished by pre-absorption of 077.2 $CRIP_{1a}$ rabbit antiserum with antigen peptide. A. $CRIP_{1a}$ immunoreactivity in the molecular layer (ML) and granule cell layer (GCL) of the cerebellar cortex; the Purkinje cell layer (PCL) contains little or no immunostaining. B. $CRIP_{1a}$ -immunostaining as seen in (A) is abolished by pre-absorption of the $CRIP_{1a}$ antiserum with 20 μ M of the antigen peptide, KPNETRSLMWVNKESFL (C-terminal region of $CRIP_{1a}$). Scale bar = 33 μ m.



Supplemental Figure 4. Ligand pretreatment of CB₁-HEK and CB₁-HEK-CRIP_{1a} cells does not alter basal [³⁵S]GTP γ S binding. Cells were pretreated for 4 hr with 10 µM WIN55,212-2, 6 µM THC or vehicle. Membranes were incubated as described in Methods with 100 mM NaCl, 10 µM GDP, 0.1 nM [³⁵S] GTP γ S. Data are mean [³⁵S]GTP γ S binding (fmol/mg) ± SEM (n = 4).



Supplemental Figure 5. Effects of stable CRIP_{1a} over-expression and knockdown on CRIP_{1a} and CB₁R mRNA and protein levels. *A* and *B*, Quantification of CRIP_{1a} (*A*) and CB₁R (*B*) transcript levels in N18TG2 WT (WT), N18TG2 empty vector (Control), and stable CRIP_{1a} over-expression and knockdown clones. qPCR data were normalized to eno2, and relative mRNA abundance was expressed as the difference in CT values, relative to WT (expressed as 1). *C* and *D*, Western blot quantification of CRIP_{1a} and CB₁R protein expression in WT, Control, and stable CRIP_{1a} over-expression and knockdown clones. Immunoreactive band densities for CRIP_{1a} (*C*) and CB₁R (*D*) were normalized to GAPDH and expressed relative to WT cells (represented as 100%). qPCR and Western blotting were performed as described in material and methods. qPCR and Western blot data were calculated from three independent experiments, and are expressed as the mean ± S.E.M. *p<0.05, #p<0.01 indicates significantly different from WT cells using Student's *t*-test.



Supplemental Figure 6. Effect of $CRIP_{1a}$ knockdown and over-expression on concentrationeffect curves of ligand-modulated [³⁵S]GTP_YS binding in N18TG2 neuroblastoma cell membranes. Membranes from wild-type N18TG2 cells or N18TG2 cells with siRNA-mediated knockdown ($CRIP_{1a}$ -KD; clone 2F) or overexpression ($CRIP_{1a}$ -OX; clone 5) of $CRIP_{1a}$ were incubated as described in Methods with 100 mM NaCl, 20 µM GDP, 0.1 nM [³⁵S] GTP_YS and varying concentrations of WIN55,212-2 (WIN), methanandamide (MAEA) or rimonabant (RIM). Data are mean % stimulation ± SEM (n = 4-9).



Supplemental Figure 7. $CRIP_{1a}$ over-expression does not affect orlistat-sensitive 2-AG levels in extracts from N18TG2 cells or membranes. N18TG2 cells with and without stable co-transfection of $CRIP_{1a}$ were incubated for 2 hr in 1 µM tetrahydrolipstatin (orlistat). Endocannabinoids were extracted from A) intact cells or B) membrane homogenates (as described in Methods). Data are mean nmol/10⁷ cells ± SEM (n = 5). No CRIP, no transfection of $CRIP_{1a}$; $CRIP_{1a}$, stable transfection of $CRIP_{1a}$.